Angiographic pattern of in-stent restenosis (ISR) after drug-eluting stent (DES) implantation different to that after bare metal stent (BMS), but their subsequent TLR rate was similar to both types of DES.
An investigational drug-eluting stent called Xience, coated with everolimus, led to significantly less late lumen loss after nine months than did the Taxus (paclitaxel-eluting) stent, said researchers here today. March 2007
An investigational bioabsorbable coronary artery stent, in its first human trials, showed acceptable safety, with efficacy better than bare-metal devices but well short of drug-eluting devices, Dutch researchers said here.
FDA says drug-eluting stents are safe & effective in stable patients with single-vessel disease; even so, they'll have to take Plavix (clopidogrel) & aspirin for a year or more...up to a lifetime. High-risk patients with multivessel disease are much more
Articles on the various questions, problems, and controversies currently plaguing drug-eluting stents: deployment techniques, stent qualities, antiplatelet therapies, and etiologies of post-DES thrombosis and restenosis.
We must optimize stent deployment & maintain a registry of how well (or poorly) we use drug-eluting stents. Instead of asking “Which stent?” or “How much anti-platelet therapy?” we must ask “How effectively are we deploying our stents?”